We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Oct 21, 2021
The role of neoadjuvant chemotherapy in predominant variant muscle-invasive bladder cancer remains unproven in a phase III trial, and these patients are generally taken to upfront surgery. Patients with a minor variant histology component are treated similar to conventional urothelial carcinoma, but there are no definitive data to guide the therapy of those with a major or pure variant component. Some histological variants are associated with adverse outcomes, particularly micropapillary, plasmacytoid and small cell histology. However, other data suggest that only the pure variants predominantly micropapillary or small cell and not mixed variant histologies mostly with squamous, adenocarcinoma, sarcomatoid and lymphoepithelioma components were associated with poor outcomes. The role of trimodality therapy (TMT) or chemoradiation in variant histology MIBC is also unclear. One retrospective analysis suggested no detrimental impact of mixed variant urothelial carcinoma histology (Krasnow et al, EUROPEAN UROLOGY 7 2 ( 2 0 1 7 ) 5 4 – 6 0). The role of adjuvant therapy is also unclear with predominant variant urothelial carcinoma histology. A large NCDB analysis (Berg et al, Cancer ) reported that only patients with pure urothelial carcinoma had an overall survival benefit associated with adjuvant chemotherapy, whereas no benefit was observed for those with variant histology. The adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection is approved by the US FDA. Thus, the use of adjuvant nivolumab with predominant urothelial histology and minor variant component is reasonable. The role of adjuvant nivolumab in those with predominant or pure variant histology needs further study. I would consider adjuvant nivolumab even in those with predominant variant urothelial carcinoma histology, especially if the PD-L1 expression is high (but not in pure variant carcinoma).
Dec 03, 2021
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.